How should sulfite oxidase deficiency be diagnosed and managed in an infant or young child presenting with progressive neurodevelopmental decline, seizures, hypotonia, and cataracts?

Sulfite Oxidase Deficiency: Diagnosis and Management

In an infant presenting with progressive neurodevelopmental decline, seizures, hypotonia, and cataracts, immediately test urine for elevated sulfite, thiosulfate, and S-sulfocysteine to diagnose isolated sulfite oxidase deficiency (ISOD), then confirm with plasma amino acids showing elevated S-sulfocysteine and genetic testing of the SUOX gene. This devastating neurometabolic disorder requires urgent recognition as it mimics hypoxic-ischemic encephalopathy but has distinct biochemical markers and a uniformly poor prognosis 1, 2.

Clinical Presentation

ISOD typically presents within the first days to weeks of life with:

• Refractory seizures or abnormal movements (present in all reported cases)
• Hypotonia progressing to spasticity
• Rapid developmental regression
• Progressive microcephaly
• Ectopia lentis (lens dislocation) - detected in approximately 40% of cases, but often appears late in the disease course 1, 3

The median age of disease onset is 3 days, with a concerning median diagnostic delay of 5.7 months 4. This delay occurs because the presentation mimics HIE and routine metabolic screening does not detect the characteristic abnormal metabolites 5.

Diagnostic Approach

Immediate Biochemical Testing

1. Urine sulfite testing (positive in all but one reported case):

   • Use fresh urine sample
   • Elevated urinary sulfite, thiosulfate, and S-sulfocysteine are pathognomonic
   • Critical pitfall: Standard metabolic screening does not detect these compounds 5

2. Plasma amino acids:

   • Elevated S-sulfocysteine (elevated in all reported cases) 1
   • Low or undetectable plasma cystine
   • Plasma total homocysteine is typically NOT elevated (distinguishes from molybdenum cofactor deficiency) 1

3. Plasma uric acid: Normal (helps differentiate from molybdenum cofactor deficiency, which shows low uric acid)

Confirmatory Testing

• Genetic analysis of SUOX gene: Identifies biallelic pathogenic variants 2, 6
• Fibroblast enzyme assay: Demonstrates absent sulfite oxidase activity 3

Neuroimaging

Brain MRI findings are characteristic and progressive:

• Bilateral subcortical multi-cystic encephalomalacia
• Predominantly affects parieto-occipital regions
• Progressive cerebral atrophy and ventriculomegaly
• Mimics severe HIE pattern 2, 5

Management

Acute Phase

There is no effective disease-modifying therapy for ISOD 6. Management is entirely supportive:

1. Seizure control: Aggressive anticonvulsant therapy (seizures are typically refractory)
2. Nutritional support: Low-methionine, low-cysteine diet has been attempted but shows minimal benefit 1
3. Symptomatic medications: Thiamine and dextromethorphan have been tried without clear efficacy 1

Important Clinical Context

Only 2 patients in the literature showed any clinical improvement with dietary therapy, and both presented after 6 months of age with relatively mild developmental delays 1. For neonatal-onset cases (the vast majority), the prognosis is uniformly devastating with:

• Median survival of 60 months 4
• Progression to profound psychomotor retardation
• Spastic quadriplegia
• Blindness
• Persistent refractory seizures 5, 7, 3

Differential Diagnosis

Molybdenum cofactor deficiency (MoCD) is the primary alternative diagnosis and presents identically to ISOD. Key distinguishing features:

Feature	ISOD	MoCD
Plasma homocysteine	Normal/undetectable	Elevated
Plasma uric acid	Normal	Low
Urinary xanthine/hypoxanthine	Normal	Elevated
Treatment available	No	Yes (fosdenopterin for MoCD-A) [6]

This distinction is critical because MoCD type A has recently become treatable with synthetic cPMP (fosdenopterin), making rapid differentiation essential 6.

Genetic Counseling

• Autosomal recessive inheritance
• Both parents are obligate heterozygous carriers
• 25% recurrence risk for future pregnancies
• Prenatal diagnosis is possible through chorionic villus sampling for SUOX enzyme activity or genetic testing 7
• Early diagnosis in subsequent pregnancies allows for informed decision-making, though no prenatal intervention exists

Key Clinical Pitfalls

1. Misdiagnosis as HIE: The neonatal presentation with seizures and encephalopathy mimics birth asphyxia; maintain high suspicion in any neonate with severe encephalopathy and refractory seizures
2. Waiting for lens dislocation: Ectopia lentis is a late finding and should not delay diagnostic testing 5
3. Relying on routine metabolic screens: Standard newborn screening and basic metabolic panels will not detect ISOD 5
4. Missing the therapeutic window for MoCD: Failure to distinguish ISOD from MoCD delays potentially life-saving treatment with fosdenopterin 6